

# ***Molecular Design and Synthesis of Certain New Quinoline Derivatives having Potential Anticancer Activity***

Thesis presented by:

***Rasha Mohamed Mohamed Mohamed Aly***

*BSc. In pharmaceutical Sciences May 2005*

*Instructor of Pharmaceutical Chemistry-NODCAR*

*(National Organization of Drug Control And Research)*

*Submitted for the partial fulfillment of the Master Degree  
In Pharmaceutical Sciences (Pharmaceutical Chemistry)*

Under the supervision of:

**Prof. Dr.Dalal Abd Alrahman Abou El-Ella**

*Professor of Pharmaceutical Chemistry*

*Ain Shams University*

**Dr. Amira Mohamed El- Metwally**

*Researcher of Organic Chemistry*

*National Organization of Drug Control And Research*

**Dr. Diaa Abdel Samea Ibrahim**

*Researcher of Organic Chemistry*

*National Organization of Drug Control And Research*

**Faculty of Pharmacy, Ain Shams University**

***Cairo, 2013***



## *Acknowledge*

Firstly, I thank and praise **ALLAH**  
in a compromise to complete access to this work.

*I would like to express my sincere gratitude to **Dr. Dalal A.Abou El Ella**,  
Professor of Pharmaceutical Chemistry; Ain shams University, for her kind suggestion of  
the point of this research and supervision in writing this thesis. I want to express my  
appreciation to her valuable advice, constant support and continuous guidance during all  
stages of this work. She's profoundly thanked for her accuracy and great experience in  
pharmaceutical chemistry. No words can describe my gratitude to her.*

*I am extremely grateful and thankful to **Dr. Amira Mohamed El- Metwally**,  
Researcher of Organic Chemistry; NODCAR, for her supervision, untiring help,  
chemicals support, valuable assistance and constant encouragement throughout the  
whole practical work and during writing this thesis. I really thank her  
for her great support and supervision.*

*I am heartily thankful and sincerely appreciated to **Dr. Diao Abdel Samea Ibrahim**,  
Researcher of Organic Chemistry, NODCAR, for his encouragement, guidance,  
motivation, enthusiasm, and immense knowledge which enabled me to understand  
the drug design, molecular modeling and practical work in experimental field  
of chemistry beside his great role in supervision on thesis writing . I am extremely  
grateful to his sincere guidance, fruitful indispensable opinion, continuous interest and  
tremendous support throughout the whole work. I introduce my sincere appreciation to  
him for all i have learned from him and for his continuous help and support in  
all stages of this thesis.*

*I would also like to thank **Dr.Ahmed Esmat**,  
Lecturer of Pharmacology and Toxicology, Faculty of pharmacy; Ain shams University,  
Cairo, Egypt, for his great effort in performing the biological activity tests,  
He's profoundly thanked for his effort, support, and experience.*



# *Dedication*

*I have to thank my **Mother** and **Father**  
for their love, support in my life, believing in me  
and praying for me. Without whom I could not  
have made this thesis.*

*Thank you both for giving me strength to reach  
the stars and chase my dreams.*

*I dedicate this thesis for you with all my love.*

*Many thanks for my sisters; **Marwa**, **Eman** and **Heba**  
for their love, support, encourage and praying for me.*

*I would like to thank **Amany wahba**,  
**Azza Awad**, **Hend Ezzat**, and **Safee Mahmoud** for  
Supporting me in performing the analysis in this thesis.*

*Thanks to all my friends,  
especially **Amany Morsi**, **Sara El-Monaieri** and **Hanady Amer**  
who always help, encourage and support me.*

*I have to thank **Crystal libraries** for  
their effort and accuracy in printing this thesis.*

*Thanks for every person encouraging,  
supporting and helping me to introduce this thesis.*

**THANKS GOD**



<b>Contents</b>	<b>i</b>
List of figures	v
List of tables	ix
List of abbreviations	x
Abstract	xiii
<b>1. Introduction</b>	<b>1</b>
1.1. What is cancer?	2
1.2. The size of cancer problem	2
1.3. Types of cancer	3
1.4. Cancer causes and risk factors	3
1.5. Cancer symptoms	3
1.6. Biological properties of cancer cells	4
1.7. Cancer treatment	4
1.7.1. Surgery	5
1.7.2. Radiotherapy	5
1.7.3. Hormone-based therapy	6
1.7.4. Biotherapy	6
1.7.5. Chemotherapy	6
1.7.5.1. Antimetabolites	7
1.7.5.2. Drugs that inhibit hormone action	8
1.7.5.3. Drugs acting via radical species, photosensitizers and photodynamic therapy of cancer	8
1.7.5.4. DNA alkylating agents	9
1.7.5.5. Compounds interacting with DNA minor groove	10
1.7.5.6. DNA topoisomerase inhibitors	11
1.7.5.7. Drugs targeting Tubulin and Microtubules	11
1.7.5.8. Drugs that inhibit signaling pathways for tumor cell growth and proliferation	13
1.8. Protein kinases	13
1.8.1. Serine/threonine protein kinase	14
1.8.2. Dual-specificity kinases	14
1.8.3. Histidine Kinases	15
1.8.4. Tyrosine kinases	15
1.8.4.1. Non Receptor Tyrosine Kinases (NRTKs)	17
1.8.4.2. Receptor Tyrosine Kinases (RTKs)	17
1.8.4.3. EGF and EGFR	18
1.8.4.4. EGFR and cancer	19
1.8.4.5. EGFR structure and regulation of activity	20
1.8.4.6. The binding of EGF to EGFR	21
1.8.5. The ATP-binding site	23
1.8.6. Types of kinase inhibitors	24
1.8.6.1. Competitive inhibitors (type I)	24

1.8.6.2. Type II inhibitors.....	26
1.8.6.3. Allosteric inhibitors (type III).....	26
1.8.6.4. Covalent inhibitors.....	27
1.8.7. Anilinoquinazoline as EGFR inhibitors.....	28
1.8.8. Antineoplastic anilinoquinolines.....	30
1.9. Quinoline.....	30
1.9.1. Quinoline properties.....	31
1.9.2. Quinolines Synthesis.....	32
1.9.2.1. Quinolines from aryl-amines and 1, 3-dicarbonyl compounds.....	32
1.9.2.2. Quinolines from aryl amines and $\alpha$ , $\beta$ -unsaturated carbonyl compounds.....	32
1.9.2.3. Conrad–Limpach synthesis.....	33
1.9.2.4. Gould–Jacobs reaction.....	33
1.9.2.5. Niementowski quinoline synthesis.....	34
1.9.2.6. Quinoline from enamines.....	34
<b>2. Rationale and Design</b> .....	36
2.1. Rationale and drug design of diagnostic anilinoquinoline TK inhibitors.....	37
2.2. Synthetic schemes.....	41
2.2.1. Scheme (1) for synthesis of starting materials <b>IVa-c</b> .....	41
2.2.2. Scheme (2) for synthesis of intermediates <b>VIIa-f</b> and final compounds <b>VIIg-i</b> .....	42
2.2.3. Scheme (3) for synthesis of intermediates <b>IXa-c</b> and final compounds <b>IXd-i</b> .....	43
2.2.4. Scheme (4) for synthesis of final compounds <b>Xa-f</b> , <b>XIa-c</b> and <b>XIIa-c</b> .....	44
<b>3. Results and discussion</b> .....	45
3.1. Chemistry.....	46
3.1.1. Scheme (1).....	46
3.1.2. Scheme (2).....	47
3.1.3. Scheme (3).....	51
3.1.4. Scheme (4).....	53
3.2. Biological evaluation.....	59
3.2.1. Cytotoxicity assay.....	60
3.2.1.1. Discussion of the results.....	68
3.2.1.2. Conclusion.....	68
3.2.2. Biochemical assay (EGFR protein kinase inhibitor activity).....	69
3.2.2.1. Evaluation of the newly synthesized targeted compounds at concentration 10 $\mu$ M against EGFR TK target.....	69
3.2.2.1.1. Results and discussion.....	70
3.2.2.1.2. Conclusion.....	71
3.2.2.2. IC <sub>50</sub> Determination for compound <b>Xb</b> and <b>Xf</b> against EGFR.....	71
<b>4. Molecular modeling</b> .....	73
4.1. Introduction.....	74
4.2. The molecular modeling techniques.....	74



4.2.1. Pharmacophore model development.....	74
4.2.1.1. Training set selection and conformational modeling.....	75
4.2.1.2. Common features pharmacophores.....	75
4.2.1.3. Mapping of the proposed compounds.....	78
4.2.2. Docking and binding energy calculations.....	80
4.3. Results and discussion: quantum docking correlation .....	96
4.4. Methodology .....	101
4.4.1. Pharmacophore model development.....	101
4.4.1.1. Training set building and conformational modeling.....	101
4.4.1.2. Common features pharmacophores.....	102
4.4.1.3. Mapping of the proposed compounds.....	102
4.4.2. Docking (C-Docker).....	102
4.4.2.1. Loading the EGFR enzyme from protein data bank (PDB).....	102
4.4.2.2. Preparation of the enzyme.....	102
4.4.2.3. Identifying the binding pocket.....	103
4.4.2.4. Display lead-protein interactions.....	103
4.4.2.5. Docking of lead compound.....	103
4.4.2.6. Displaying the docking scores.....	103
4.4.2.7. Validation of the lead compound docking and selection of proper binding pose .....	103
4.4.2.8. Docking of the reference compound (70) and proposed compounds.....	104
4.4.2.8.1. Loading the reference compound (70) and proposed compounds.....	104
4.4.2.8.2. Interactive docking .....	104
4.4.2.8.3. Displaying the docking scores.....	104
4.4.3. Binding energy.....	104
4.4.3.1. Minimization.....	104
4.4.3.2. Binding energy calculations.....	105
4.4.3.3. Displaying the binding pattern of the ligand (22), reference compound (70) and promising compounds (2D and 3D).....	105
4.4.4. Quantum docking correlation.....	105
4.5. Final conclusion.....	106
<b>5. Experimental.....</b>	<b>108</b>
5.1. Chemistry.....	109
5.1.1. Materials and methods.....	109
5.1.2. Synthesis.....	110
5.2. Biological evaluation of compounds.....	153
5.2.1. Cytotoxicity assessment.....	153
5.2.1.1. Methodology.....	153
5.2.1.1.1. Cell culture.....	153
5.2.1.1.2. SRB cytotoxicity assay.....	153
5.2.2. Biochemical Assay (EGFR protein kinase inhibitor activity).....	153

5.2.2.1. Evaluation of synthesized compounds at concentration 10 $\mu$ M against EGFR TK target.....	153
5.2.2.1.1. Materials: quality control and reagents.....	154
5.2.2.1.2. Methodology.....	154
5.2.2.1.3. Protein kinase (PK) assays.....	154
5.2.2.2. IC <sub>50</sub> Determination for compound <b>Xb</b> and <b>Xf</b> against EGFR.....	155
<b>6. References</b> .....	156

**List of figures:**

1. <b>Figure (1):</b> Cancer treatment methods.....	5
2. <b>Figure (2):</b> Main types of reversible interactions with DNA.....	10
3. <b>Figure (3):</b> Microtubules and tubulin structures.....	12
4. <b>Figure (4):</b> Dynamic equilibrium between microtubules and tubulin dimers.....	12
5. <b>Figure (5):</b> Protein phosphorylation and dephosphorylation.....	14
6. <b>Figure (6):</b> Tyrosine kinases classification .....	16
7. <b>Figure (7):</b> Inactive form of tyrosine kinase: prior to binding of an activating ligand.....	17
8. <b>Figure (8):</b> Mechanisms leading to EGFR oncogenic signaling.....	19
9. <b>Figure (9):</b> EGFR composition and EGFR-ligand complex.....	20
10. <b>Figure (10):</b> Binding of EGF to EGFR.....	21
11. <b>Figure (11):</b> Binding of ligand to EGFR leads to receptor dimerization, autophosphorylation and activation of several downstream signaling pathways.....	22
12. <b>Figure (12):</b> Interactions of ATP in the catalytic domain of EGFR.....	23
13. <b>Figure (13):</b> The binding of kinase inhibitors type I: (a) CX4945 (27) and (b) Lapatinib (22); the protein kinase is shown in grey color.....	25
14. <b>Figure (14):</b> The binding of kinase inhibitors type II: Imatinib (28) .....	26
15. <b>Figure (15):</b> The binding of kinase allosteric inhibitors: compound (30).....	27
16. <b>Figure (16):</b> Mechanism of action of irreversible EGFR inhibitors, e.g. E KI-785(31) ...	28
17. <b>Figure (17):</b> Structure-activity relationship in 4-anilinoquinazolines as EGFR inhibitors.....	28
18. <b>Figure (18):</b> Quinoline (39) resonance structures. ....	32
19. <b>Figure (19):</b> Similarities of pharmacophore features between target compounds ( <b>VIIg-i</b> , <b>IXd-i</b> , <b>Xa-f</b> , <b>Xia-c</b> and <b>XIIa-c</b> ) and references compounds (Lapatinib (22) and compound (70)).....	39
20. <b>Figure (20):</b> Molecular field analysis of 4-anilinoquinazoline, 4-anilinoquinoline-3-carbonitrile and 4-anilinoquinoline-3-carboxamide [cyan: quinazoline as a reference; pink: 3-cyanoquinoline (similarity = 0.823) and orange: quinoline-3-carboxamide (similarity = 0.868)] .....	40
21. <b>Figure (21):</b> N-aryl cyanoacetamides synthesis.....	46

22. Figure (22): Reaction of DMFDMA with cyanoacetamides .....	47
23. Figure (23): Reaction mechanism of N-aryl cyanoacetamides <b>IVa-c</b> with DMFDMA.....	48
24. Figure (24): Reaction mechanism of cyanoacrylamide derivatives <b>VIIa-i</b> .....	50
25. Figure (25): Mechanism of quinoline-3-carboxamide derivatives <b>IXa-i</b> .....	52
26. Figure (26): Claisen-Schmidt condensation. ....	53
27. Figure (27): Mechanism of the formation of $\alpha$ , $\beta$ -unsaturated keto derivatives <b>Xa-f</b> from 6-acetyl quinoline-3-carboxamide derivatives <b>IXa-c</b> and aromatic aldehydes.....	55
28. Figure (28): Thiazole synthesis.....	56
29. Figure (29): Mechanism of the formation of 6-(2-aminothiazole)quinoline-3-carboxamide derivatives <b>XIa-c</b> .....	57
30. Figure (30): Reaction of amine with phenyl isothiocyanate .....	58
31. Figure (31): Mechanism of 6-(thiourea)quinoline-3-carboxamide derivatives <b>XIIa-c</b> formation from 6-(2-aminothiazole)quinoline-3-carboxamide derivatives <b>XIa-c</b> and phenyl isothiocyanate.....	59
32. Figure (32): $IC_{50}$ of Doxorubicin ( <b>10</b> ).....	60
33. Figure (33): $IC_{50}$ of compound <b>VIIg</b> .....	61
34. Figure (34): $IC_{50}$ of compound <b>VIIh</b> .....	61
35. Figure (35): $IC_{50}$ of compound <b>VIIIi</b> .....	61
36. Figure (36): $IC_{50}$ of compound <b>IXd</b> .....	62
37. Figure (37): $IC_{50}$ of compound <b>IXe</b> .....	62
38. Figure (38): $IC_{50}$ of compound <b>IXf</b> .....	62
39. Figure (39): $IC_{50}$ of compound <b>IXg</b> .....	63
40. Figure (40): $IC_{50}$ of compound <b>IXh</b> .....	63
41. Figure (41): $IC_{50}$ of compound <b>IXi</b> .....	63
42. Figure (42): $IC_{50}$ of compound <b>Xa</b> .....	64
43. Figure (43): $IC_{50}$ of compound <b>Xb</b> .....	64
44. Figure (44): $IC_{50}$ of compound <b>Xc</b> .....	64
45. Figure (45): $IC_{50}$ of compound <b>Xd</b> .....	65
46. Figure (46): $IC_{50}$ of compound <b>Xe</b> .....	65

<b>47. Figure (47):</b> <i>IC<sub>50</sub> of compound Xf</i> .....	65
<b>48. Figure (48):</b> <i>IC<sub>50</sub> of compound XIa</i> .....	66
<b>49. Figure (49):</b> <i>IC<sub>50</sub> of compound XIb</i> .....	66
<b>50. Figure (50):</b> <i>IC<sub>50</sub> of compound XIc</i> .....	66
<b>51. Figure (51):</b> <i>IC<sub>50</sub> of compound XIIa</i> .....	67
<b>52. Figure (52):</b> <i>IC<sub>50</sub> of compound XIIb</i> .....	67
<b>53. Figure (53):</b> <i>IC<sub>50</sub> of compound XIIc</i> .....	67
<b>54. Figure (54):</b> <i>Graph of log compounds Xb and Xf concentrations against % inhibition of activity.</i> .....	72
<b>55. Figure (55):</b> <i>The thirty literature compounds used as a training set in the pharmacophore building with their IC<sub>50</sub> values</i> .....	76
<b>56. Figure (56):</b>	
a) <i>The common features pharmacophore generated from training set; two hydrophobic centers (1, 2; cyan color), one HBD (magenta color) and two HBA (green color)</i> .....	77
b) <i>The common features pharmacophore generated from training set including the distance between the five generated features</i> .....	78
<b>57. Figure (57):</b>	
a) <i>Mapping of reference compound [Lapatinib (22), fit value = 4.91551] on the generated high ranked pharmacophore</i> .....	78
b) <i>Mapping of reference compound [compound (70), fit value = 4.50162] on the generated high ranked pharmacophore</i> .....	79
<b>58. Figure (58):</b>	
a) <i>Mapping of compound VIIg (fit value = 3.7296) on the generated high ranked pharmacophore</i> .....	79
b) <i>Mapping of compound IXg (fit value = 3.97321) on the generated high ranked pharmacophore.</i> .....	80
<b>59. Figure (59):</b>	
a) <i>H-Bond interactions of reference compound [Lapatinib (22)] with the active site of EGFR (from PDB; 1 H-bond with MET 793)</i> .....	93
b) <i>H-Bond interactions of reference compound [Lapatinib (22)] with the active site of EGFR (DS 2.5; RMSD: 0.97, 1H-bond with MET 793; binding energy: - 47.468)</i> .....	94
c) <i>H-Bond interactions of reference compound (70) with the active site of EGFR (by DS 2.5; 2 H-bonds with MET 793 and ASP 855; binding energy: -43.5268)</i> .....	94
<b>60. Figure (60):</b>	
a) <i>H-Bond interactions of compounds VIIg with the active site of EGFR (no H-bonds; binding energy -38.6957)</i> .....	95

b) H-Bond interactions of compound <b>Xd</b> with the active site of EGFR (2 H-bonds with MET 793; binding energy -40.4646).....	95
c) H-Bond interactions of compound <b>Xa</b> with the active site of EGFR(3 H-bonds with MET 793, THR 854 and GLN 791; binding energy -35.6041).....	96
<b>61. Figure (61):</b> Overlay of compound <b>Xa</b> (in grey color) on Lapatinib ( <b>22</b> ) (in green color) according to the result of quantum docking.....	97
<b>62. Figure (62):</b> Overlay of compound <b>Xb</b> (in grey color) on Lapatinib ( <b>22</b> ) (in green color) according to the result of quantum docking.....	97
<b>63. Figure (63):</b> Overlay of compound <b>Xf</b> (in grey color) on Lapatinib ( <b>22</b> ) (in green color) according to the result of quantum docking.....	98
<b>64. Figure (64):</b> Unfavorable interaction of <b>Xa</b> with the active site.....	98
<b>65. Figure (65):</b> Favorable interaction of compound <b>Xb</b> with the active site of EGFR.....	99
<b>66. Figure (66):</b> Favorable interaction of compound <b>Xf</b> with the active site of EGFR.....	99
<b>67. Figure (67):</b> H-Bond interactions of compound <b>Xb</b> with the active site of EGFR (2 H-bonds with CYS 797 and ARG 841; binding energy -34.2012).....	100
<b>68. Figure (68):</b> H-Bond interactions of compound <b>Xf</b> with the active site of EGFR (no H-bonds; binding energy -39.7814).....	101

**List of tables:**

<b>1. Table (1):</b> <i>The HER family members and their dysregulation effect in the development of cancer.....</i>	<i>18</i>
<b>2. Table (2):</b> <i>The results of EGFR TK inhibition activity and antitumor activity assays.....</i>	<i>69</i>
<b>3. Table (3):</b> <i>% Activity change of EGFR target in the presence of compounds <b>Xb</b> and <b>Xf</b> and their IC<sub>50</sub> values.....</i>	<i>72</i>
<b>4. Table (4):</b> <i>The newly synthesized compounds with their promising fit-values, -C-docker energy, -C-docker interaction energy and binding energy compared with Lapatinib (<b>22</b>) and compound (<b>70</b>).....</i>	<i>81</i>
<b>5. Table (5):</b> <i>The interactions of the promising compounds which were selected for synthesis with EGFR.....</i>	<i>82</i>